The Prevalence of Metabolic Syndrome in Patients on Hemodialysis and Peritoneal Dialysis: A Comparative Study

Document Type : Original Article (s)

Authors

1 Assistant Professor, Isfahan Kidney Diseases Research Center, Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Associate Professor, Isfahan Kidney Diseases Research Center, Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Associate Professor, Department of Community Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

4 Student of Medicine, Student Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: One of the major causes of mortality in patients with kidney failure requiring dialysis is cardiovascular diseases. Metabolic syndrome refers to a collection of metabolic disorders that causes systemic inflammation and therefore plays an important role in increasing the incidence of cardiovascular disorders and the associated mortality and morbidity. Given the increasing prevalence of metabolic syndrome in the general population, this study was designed to investigate the prevalence of metabolic syndrome in patients on peritoneal dialysis and hemodialysis.Methods: A cross-sectional study on 170 patients on dialysis was performed in Alzahra Hospital, Isfahan, Iran. Blood samples were obtained to examine glucose, lipid profile, hemoglobin, albumin, parathyroid hormone (PTH), calcium, phosphorus, and white blood cell count (WBC). Blood pressure, weight, height, and waist circumference were also measured by standard methods. The information of patients was recorded in a questionnaire.Findings: Metabolic syndrome was observed in 67% of the studied population. The prevalence of metabolic syndrome was higher in females than males (77% vs. 57%). The syndrome was also more prevalent among peritoneal dialysis patients than individuals on hemodialysis (73% vs. 47%). The highest prevalence in hemodialysis patients was seen in patients who were dialyzed through a temporary catheter. The average weight, body mass index, albumin levels, and WBC were significantly higher in patients with metabolic syndrome. However, the differences in hemoglobin, PTH, calcium, and phosphorus values were not statistically significant between patients with and without metabolic syndrome. Conclusion: The prevalence of metabolic syndrome is high in dialysis, especially in peritoneal dialysis, patients. In addition, women are more at risk than men. Therefore, in order to prevent cardiovascular mortality and morbidity, these patients need to be regularly examined to diagnose and treat the risk factors of metabolic syndrome as soon as possible.

Keywords

References

  1. United States Renal Data System. USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and kidney Disease; 2004.
  2. Sarrafzadegan N, Kelishadi R, Baghaei A, Hussein SG, Malekafzali H, Mohammadifard N, et al. Metabolic syndrome: an emerging public health problem in Iranian women: Isfahan Healthy Heart Program. Int J Cardiol 2008; 131(1): 90-6.
  3. Li PKT, Kwan BCH, Szet CC, Ko GTC. Metabolic syndrome in peritoneal dialysis patients. NDT Plus 2008; 1(4): 206-14.
  4. Wortmann RL. Disorderse of purin and pyrimidine metabolism. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, et al., editors. Harrison's Principles of Internal Medicine. 16th ed. New York: McGraw-Hill; 2005. p. 2311.
  5. Flanigan MJ, Lim VS. Endocrine disturbances. In: Daugirdas JT, Blake PG, Ing TS, editors. Handbook of Dialysis. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 575.
  6. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486-97.
  7. Wang J, Ruotsalainen S, Moilanen L, Lepisto P, Laakso M, Kuusisto J. The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns. Eur Heart J 2007; 28(7): 857-64.
  8. Brunier GM, Graydon J. The influence of physical activity on fatigue in patients with ESRD on hemodialysis. ANNA J 1993; 20(4): 457-61.
  9. Ebrahimi-Mamaghani M, Arefhosseini SR, Golzarand M, Aliasgarzadeh A, Vahed-Jabbary M. Long-term effects of processed berberis vulgaris on some metabolic syndrome components. IJEM 2009; 11(1): 41-7.
  10. Delavari A, Forouzanfar MH, Alikhani S, Sharifian A, Kelishadi R. First nationwide study of the prevalence of the metabolic syndrome and optimal cutoff points of waist circumference in the Middle East: the national survey of risk factors for noncommunicable diseases of Iran. Diabetes Care 2009; 32(6): 1092-7.
  11. Gharipour M, Kelishadi R, Baghaie M, Rabiei K. Metabolic syndrome in an Iranian adult population. Europ Heart J 2006; 27(Suppl): 250-1.
  12. Tsangalis G, Papaconstantinou S, Kosmadakis G, Valis D, Zerefos N. Prevalence of the metabolic syndrome in hemodialysis. Int J Artif Organs 2007; 30(2): 118-23.
  13. Criteria for measuring metabolic syndrome prevalence in Iran revealed Diabetes. Res Clin Pract, Advance Online publication; 2007.
  14. Young DO, Lund RJ, Haynatzki G, Dunlay RW. Prevalence of the metabolic syndrome in an incident dialysis population. Hemodial Int 2007; 11(1): 86-95.
  15. Holdaas H, Fellstrom B, Jardine A, Gimpelewicz C, Staffler B, Logan J. Prevalence and consequences of metabolic syndrome in a renal transplant population. American Society of Nephrology (ASN) Renal Week; 2004.
  16. Azizi F, Salehi P, Etemadi A, Zahedi-Asl S. Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study. Diabetes Res Clin Pract 2003; 61(1): 29-37.
  17. Ucar E, Huzmeli C, Guven O, Savas N, Gullu M, Asilyoruk S, et al. Frequency of metabolic syndrome among hemodialysis patients according to NCEP-ATP III and IDF definitions. Ren Fail 2009; 31(3): 221-8.
  18. Johnson DW, Armstrong K, Campbell SB, Mudge DW, Hawley CM, Coombes JS, et al. Metabolic syndrome in severe chronic kidney disease: Prevalence, predictors, prognostic significance and effects of risk factor modification. Nephrology (Carlton) 2007; 12(4): 391-8.
  19. Reddan DN, Klassen PS, Szczech LA, Coladonato JA, O'Shea S, Owen WF, Jr., et al. White blood cells as a novel mortality predictor in haemodialysis patients. Nephrol Dial Transplant 2003; 18(6): 1167-73.
  20. Kalantar-Zadeh K, Kovesdy CP, Derose SF, Horwich TB, Fonarow GC. Racial and survival paradoxes in chronic kidney disease. Nat Clin Pract Nephrol 2007; 3(9): 493-506.
Journal of Isfahan Medical School
Volume 29, Issue 171 - Serial Number 171
November and December 2012
Pages 2722-2731

Files

History

  • Receive Date: 25 October 2011
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics